Jump to navigation Jump to search
Clinical data
Routes of
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass285.317 g/mol

WikiDoc Resources for Faropenem


Most recent articles on Faropenem

Most cited articles on Faropenem

Review articles on Faropenem

Articles on Faropenem in N Eng J Med, Lancet, BMJ


Powerpoint slides on Faropenem

Images of Faropenem

Photos of Faropenem

Podcasts & MP3s on Faropenem

Videos on Faropenem

Evidence Based Medicine

Cochrane Collaboration on Faropenem

Bandolier on Faropenem

TRIP on Faropenem

Clinical Trials

Ongoing Trials on Faropenem at Clinical Trials.gov

Trial results on Faropenem

Clinical Trials on Faropenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Faropenem

NICE Guidance on Faropenem


FDA on Faropenem

CDC on Faropenem


Books on Faropenem


Faropenem in the news

Be alerted to news on Faropenem

News trends on Faropenem


Blogs on Faropenem


Definitions of Faropenem

Patient Resources / Community

Patient resources on Faropenem

Discussion groups on Faropenem

Patient Handouts on Faropenem

Directions to Hospitals Treating Faropenem

Risk calculators and risk factors for Faropenem

Healthcare Provider Resources

Symptoms of Faropenem

Causes & Risk Factors for Faropenem

Diagnostic studies for Faropenem

Treatment of Faropenem

Continuing Medical Education (CME)

CME Programs on Faropenem


Faropenem en Espanol

Faropenem en Francais


Faropenem in the Marketplace

Patents on Faropenem

Experimental / Informatics

List of terms related to Faropenem

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Faropenem is an orally-active beta-lactam antibiotic belonging to the penem group. It is the first orally-active penem antibiotic. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.

  • The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (Template:PubChem)
  • The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem but company officials recently announced that this name was rejected by the FDA. (Q1 06 Investor Conf Call)(Template:PubChem)

The company also stated their hope to have the product available for commercial sale months before the 2007 influenza season.

Clinical use

Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application (NDA) dossier submitted included four proposed indications:

  • acute bacterial sinusitis
  • community acquired pneumonia
  • acute exacerbations of chronic bronchitis
  • uncomplicated skin and skin structure infections

External links

Template:WH Template:WikiDoc Sources